Tag Archives: investment

Hot Investor Mandate 1: Newly Founded Family Office Actively Seeking Early-Stage Life Science Investments, from Pre-Clinical Stage Assets to Medical Devices

15 Mar

A newly formed Delaware family office investment vehicle representing East Coast-based family interests is looking to invest in ground-breaking life science and medical device technologies. While the firm is very flexible in terms of investment size, they are generally looking to invest a minimum of $0.5 million per round. The firm is open to Investing in companies located throughout North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Device and Diagnostics Sectors that address underserved medical needs, or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis and are especially interested in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell- based therapeutics.

The firm is less interested in small molecules and generally will not consider biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease- modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency.

For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Chinese Government Partnered VC Firm Invests in Therapeutics and Clinical Testing Companies, with Focus on China Angle

15 Mar

A venture capital firm partnered with the Chinese Government was founded in 2016, and focuses on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. With the Chinese Government partnership, the firm seeks to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also willing to look at medical devices to a small degree but is not very familiar with those technologies. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Investment Arm of Major China Genomics Company Looks for Complementary Early-Stage Genomics & Big Data/AI Technologies

15 Mar

A branch of a subsidiary of a major genomics sequencing company in China is actively seeking technologies from the US, Canada, and China that will complement what they currently have. In addition to direct investments, the firm often functions as a strategic partner that can help provide a technology platform for a startup or even integrate the new technology into their system. The firm also provides access to their large marketing team once the product is developed to help the startup during their commercialization phase. The firm is currently interested in early stage companies: usually at seed to series A and is rather flexible as to the financing terms. Additionally, the firm is willing to work through either partnerships or direct investments.

The firm is actively seeking new genomics technologies. Currently, the firm is interested in any technology within diagnostics, digital health, and medtech that has a focus on genomics. Within the diagnostics and medtech sectors, the firm is particularly interested in sequencing technologies currently, but is willing to see all early stage genomics-based technologies within these sectors. For digital health, the firm is interested in companies involved in big data and AI that already have algorithms that can utilize the large pool of genomics data that the firm currently has access to.

When investing, the firm likes to take an active role in the company and prefers taking board seats but does not require a board seat. Otherwise, the firm prefers to work with companies that the firm can work with and help develop into either a potential integration or a productive partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Newly Launched USA Investment Firm Focused on Diagnostics Investments

8 Feb

A recently formed venture capital firm is focusing on the big-data aspect of personalized diagnostics. The firm is seeking early-stage companies raising seed to Series B rounds. The firm has a $200M target fund and seeks to make 15 –20 new investments within the year. The firm seeks to make $2M – $4M initial investments per company, but will make smaller initial seed investments as well. The firm prefers to be actively involved in their portfolio companies, and therefore prefers companies based near the west coast, though is open to other U.S.-based companies.

The firm is focused on early-detection diagnostics, such as discovering cancer when it is still monogenetic versus heterogeneous and already invaded in other parts of the body or detecting Alzheimer’s 8-10 years before dementia symptoms are present. The firm is interested in point-of-care diagnostics (for influenza A/B/bacterial, etc.) that can diagnose specifically and efficiently. The firm is especially interested in technology with a big-data component, and involved in genomics and personalized medicine to provide the right treatment as early as possible. The firm seeks preclinical to clinical-stage technology, though will also look later-stage depending on the opportunity.

The firm requires a smart management team that is diverse in knowledge, and a company with good IP that may come from a leading institution. The firm will usually seek early-stage companies with less than half a dozen people.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Biotech Family Offices Discuss Direct Investment at RESI Boston

24 Aug

By Lucy Parkinson, Director of Research, LSN

RESI Partnering is now open, providing attendees with the opportunity to book one on one meetings with investors.  If you log in to Partnering, you will see a wide variety of investors available to reach out to, including venture capital firms, big pharma, angels – and family offices.

RESI Boston’s Biotech Family Office sesssion features family office investors from around the world who are making direct investments into early stage drug development companies.  These firms have a variety of strategies, interests and motivations.  If you’d like to know how family office investors think about early stage drugs and what kind of technology catches their eye, this is the panel for you.

Moderated by Colin Widen (CEO, Boston Innovation Capital), the panelists are:

  • Christine Bunt (Venture Partner, 20/20 HealthCare Partners)
  • Pini Orbach (Head of Pharma, Arkin Bioventures)
  • Alex Pickett (Principal, Mediqventures)
  • Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital)

We’ve extended the RESI discounted registration until Friday, so if you want to hear from these Biotech Family Offices now is the time to get registered.

RESI San Francisco Panel Announcement: Corporate VCs & Strategic Investment

3 Nov

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking externally for innovative technologies, and strategic venture investments are a key part of many firms’ strategies for participating in the early stage ecosystem.  Firms may use subsidiary corporate venture funds, or may have an internal unit for making strategic investments in startups that are relevant to their pipeline.

At RESI San Francisco on Tuesday January 10th, the Corporate VC panel will bring together investors from 5 different corporate VCs to cover how they invest on behalf of their parent pharma companies.

The panelists are:

In this panel, corporate VC investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and how they bridge the gap between early stage startups and major pharmaceutical corporations.

If you’d like to be there in person, you can register for RESI now.

resi-san-francisco-2017

Developing a Global Target List of Prospective Investors

17 Oct
By Max Klietmann, VP of Marketing, LSN

Before moving any further, it is important to address a critical piece of the equation while looking at structuring an institutional-style fundraising campaign. The issue of referral vs. fit is one of the most misunderstood parts of the fundraising process, and countless companies fail to raise money, simply because their fundraising executives won’t believe that a cold email can be effective. We at LSN speak to a lot of entrepreneurs who refuse to accept that outbound marketing works, and it is our belief that this is due to an unwillingness to commit rather than genuine disbelief. Once you have made the commitment to go outbound, things become a little easier.

On to the issue of the cold e-mail. It has been proven time and time again that cold emails with diligent follow-up targeting the right group can be extremely effective. This is primarily because cold emails help you to reach the target person – with cold emails you can immediately reach exactly the right people in the investor organization, and that makes a significant difference. Of course this won’t work with just a random list of emails, you need a targeted list of specific entities. Beyond that, you need to reach the right people, not just the right firms.

Now that we’ve covered that, let’s look at the potential pool of investors and narrow it down to a target list. There are two types of investors: mandate-driven and opportunistic. Mandate driven investors are usually restricted to investing in opportunities that match a particular main sector, subsector, development phase, growth phase, indication preference, capital structure or need above or below a certain amount of investment. These restrictions are formed at the inception of the fund in order to provide serve as unique investment vehicle that matches the investment interests of the limited partner’s participating in the fund. By limiting the investment opportunities the limited partners can benefit from the unique risk and reward characteristics of the fund. For example an investor might specialize in investing in late stage oncology opportunities that requires equity financing. As a result opportunities outside of the mandate’s scope are immediately disqualified. Opportunistic investors on the other hand are defined by their lack of a mandate driven investment strategy. As a result they will not disqualify opportunities and therefore tend to have a broad range of investments.

As a fundraising executive you must understand each investor’s investment criteria, and make an effort to target those that are a match your company’s unique investment profile. Otherwise, you will find yourself wasting your time reaching out to investors that are not a fit. Note however, that your list should not be restricted to only fits for your current round, as you want to create a dialogue with investors that will be a fit further down the road. That way, when the next fundraising hurdle is reached, you already have a dialogue with the next source of capital.

Here’s a good benchmark to use: for every 100 investors that you reach out that that are un-validated without any clear indication of potential fit, a hit rate of 1-2 is the absolute upper limit. However, of a list of 100 investors with a pre-validated declared interest in an opportunity like yours, one should expect to schedule a conference call or meeting with 15–20 of those prospects. This is in stark contrast to the one or two prospects that you will yield from a un-targeted list. Assuming you are able to obtain a vetted target list and you’ve taken the time to evaluate your resources for follow-up, you can now get an idea of how many investors you will need on your email target list.

Generally, a fundraising executive starts be mining their internal database of potential investors—a list of current, past, and prospective investors—which they have built up over the years. This is a start, but your work is not done. To augment such a list, you can purchase one of the hundreds of commercially available databases, or take some time to research potential investors on your own.

Researching investors on your own is time consuming process, and painful process. Sophisticated investor database providers on the other hand can provide you with a list of potential investors that meet your investment profile with a couple clicks. They do this by employing staff that actively interviews investors regarding their investment preferences. Although these providers charge a fee they can save you significant time and effort.